- Home
- Publications
- Publication Search
- Publication Details
Title
The safety of bortezomib for the treatment of multiple myeloma
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2018-08-18
DOI
10.1080/14740338.2018.1513487
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
- (2018) Meletios Dimopoulos et al. Journal of Hematology & Oncology
- Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
- (2018) Heinz Ludwig et al. LEUKEMIA
- Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Progress and Paradigms in Multiple Myeloma
- (2016) Kenneth C. Anderson CLINICAL CANCER RESEARCH
- VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
- (2016) David S. Siegel et al. Clinical Lymphoma Myeloma & Leukemia
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
- (2016) A Rosenthal et al. Blood Cancer Journal
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
- (2015) P. G. Richardson et al. BLOOD
- Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma
- (2015) E. Wilson Grandin et al. JOURNAL OF CARDIAC FAILURE
- Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
- (2014) P. Sonneveld et al. BLOOD
- Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma
- (2014) M. A. Dimopoulos et al. HAEMATOLOGICA
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modified Bortezomib, Adriamycin and Dexamethasone (PAD) Regimen in Advanced Multiple Myeloma
- (2014) Yongqing Zhang et al. PATHOLOGY & ONCOLOGY RESEARCH
- Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
- (2013) U.-H. Mellqvist et al. BLOOD
- Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature
- (2012) Margarita Bockorny et al. ACTA HAEMATOLOGICA
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
- (2012) B. Arnulf et al. HAEMATOLOGICA
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
- (2012) Jesús F. San Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Biologic Impact of Proteasome Inhibition in Multiple Myeloma Cells—From the Aspects of Preclinical Studies
- (2012) Teru Hideshima et al. SEMINARS IN HEMATOLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Management of treatment-emergent peripheral neuropathy in multiple myeloma
- (2011) P G Richardson et al. LEUKEMIA
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
- (2010) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
- (2010) Annemiek Broyl et al. LANCET ONCOLOGY
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
- (2010) Michel Delforge et al. LANCET ONCOLOGY
- A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA
- (2010) Debra L. Barton et al. SUPPORTIVE CARE IN CANCER
- Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
- (2008) Sundar Jagannath et al. BRITISH JOURNAL OF HAEMATOLOGY
- High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
- (2008) Joseph R. Mikhael et al. BRITISH JOURNAL OF HAEMATOLOGY
- From Bench to Bedside: A Case of Rapid Reversal of Bortezomib-Induced Neuropathic Pain by the TRPM8 Activator, Menthol
- (2008) Leslie A. Colvin et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started